Human epidermal growth factor receptor 2(HER2)overexpression and amplification activate key pathways driving tumor progression,leading to HER2-targeted therapies.However,HER2 signaling can also be aberrantly activated...Human epidermal growth factor receptor 2(HER2)overexpression and amplification activate key pathways driving tumor progression,leading to HER2-targeted therapies.However,HER2 signaling can also be aberrantly activated by somatic mutations,independent of overexpression or amplification,contributing to tumorigenesis[1].These mutations,found in domains such as the extracellular(ECD),transmembrane(TMD)/juxtamembrane(JMD),and tyrosine kinase(KD)regions,occur across cancers,from melanoma(1%)to bladder cancer(≤12%)[1,2],suggesting a significant population could benefit from HER2-targeted treatments.Neratinib,an irreversible pan-HER tyrosine kinase inhibitor,has shown efficacy in HER2-mutated cancers and is recommended in National Comprehensive Cancer Network guidelines[3].However,resistance mechanisms,such as secondary HER2 mutations or amplifications,may limit its efficacy[4,5],highlighting the need for combination therapies.展开更多
In 2022,gastric cancer(GC)ranked as the fifth most common cancer and the third leading cause of cancer death in China,with 358,672 new cases and 260,372 deaths,accounting for 37.0%and 39.4%of global cases,respectively...In 2022,gastric cancer(GC)ranked as the fifth most common cancer and the third leading cause of cancer death in China,with 358,672 new cases and 260,372 deaths,accounting for 37.0%and 39.4%of global cases,respectively[1].Previous studies have shown that 25.9%and 36.5%of GC patients in China were diagnosed at stages III and IV,respectively,with 5-year overall survival(OS)rates of 33.0%for stage III and 5.5%for stage IV[2,3].展开更多
Large granular lymphocytic leukemia(LGLL)is a relatively uncommon malignancy of the blood system,marked by the clonal expansion of cytotoxic lymphocytes,particularly CD8+T cells(T-LGLL),and in some cases,natural kille...Large granular lymphocytic leukemia(LGLL)is a relatively uncommon malignancy of the blood system,marked by the clonal expansion of cytotoxic lymphocytes,particularly CD8+T cells(T-LGLL),and in some cases,natural killer(NK)cells(NK-LGLL).1 Though rare,LGLL is clinically significant,representing approximately 2%to 6%of all chronic lymphopro-liferative diseases,with a somewhat higher incidence in Asian populations.展开更多
Objective： The mitomycin C and cisplatin combination was investigated in patients with advanced breast cancer who had been exposed to anthracyclines, vinorelbine and taxanes. Methods： Three-weekly regimen consisted ...Objective： The mitomycin C and cisplatin combination was investigated in patients with advanced breast cancer who had been exposed to anthracyclines, vinorelbine and taxanes. Methods： Three-weekly regimen consisted of mitomycin, 6 mg/m^2 administered intravenously on day 1, and cisplatin, 25 mg/m^2 intravenously on day 1-3. Results： Thirty-eight patients aged 25-75 years （median, 46 years） were treated with an overall response rate of 31.6%. The median time to progression （TTP） was 4.0 months. Median TTP for 12 patients with a complete or partial response was 9.0 months, while stable disease and progression of disease 4.0 months, P=0.002. Grade 3/4 side effects of neutropenia, thrombocytopenia and nausea/vomiting were documented in 4 （10.5%）, 4 （10.5%） and 3 （7.9%） patients, respectively. The median overall survival was 13＊ months. Conclusion： Mitomydn C/cisplatin doublet showed antitumor activity for anthracydine-, vinorelbine- and taxane-resistant breast cancer comparable to other regimens. This well-tolerated regimen provides an affordable option for patients in China.展开更多
基金supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute(KHIDI)the Ministry of Health&Welfare,Republic of Korea(grant numbers:HI17C2206 and HA22C0012)+1 种基金Additional support was provided by a grant from the National R&D Program for Cancer Control,National Cancer Center(NCC),Ministry of Health&Welfare,Republic of Korea(grant number:HA22C0052)through the KOSMOS Molecular Tumor Board.
文摘Human epidermal growth factor receptor 2(HER2)overexpression and amplification activate key pathways driving tumor progression,leading to HER2-targeted therapies.However,HER2 signaling can also be aberrantly activated by somatic mutations,independent of overexpression or amplification,contributing to tumorigenesis[1].These mutations,found in domains such as the extracellular(ECD),transmembrane(TMD)/juxtamembrane(JMD),and tyrosine kinase(KD)regions,occur across cancers,from melanoma(1%)to bladder cancer(≤12%)[1,2],suggesting a significant population could benefit from HER2-targeted treatments.Neratinib,an irreversible pan-HER tyrosine kinase inhibitor,has shown efficacy in HER2-mutated cancers and is recommended in National Comprehensive Cancer Network guidelines[3].However,resistance mechanisms,such as secondary HER2 mutations or amplifications,may limit its efficacy[4,5],highlighting the need for combination therapies.
基金approved by the Independent Ethics Committee of Chinese PLA General Hospital(C2021-102-01)Changzhi People’s Hospital(LSPJ2022006)+17 种基金Fujian Provincial Cancer Hospital(2022-016-01)Cancer Hospital of Shandong First Medical University(SDZLEC2022-042-01)The First People’s Hospital of Changde City(2022-016-01)Jilin Cancer Hospital(202201-011-01)Linyi People’s Hospital(2022-lunlishencha-10)Liaoning Cancer Hospital and Institute(20220205)Shanxi Province Cancer Hospital(YW2022009)Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital(L2022-Y010-002)Harbin Medical University Cancer Hospital(2022-91)Anhui Provincial Cancer Hospital,The First Affiliated Hospital of University of Science and Technology of China(2022-lunlishencha-08)The Fourth Hospital of Hebei Medical University(2022044)Binzhou Medical University Hospital(2022-001-01)Central Hospital Affiliated to Shandong Medical University(jizhongxinlunlilinshen2022-011-01)Qingdao Central Hospital,University of Health and Rehabilitation Science([Y]SY202200401)Liaocheng People’s Hospital(2022006)Suining Central Hospital(2022-lunliyijian-sy002-01)Yanan University Xianyang Hospital(YDXYEC-YWPJ-2022-5)conducted in accordance with the Declaration of Helsinki and Good Clinical Practices.Written informed consent was obtained from all patients before enrollment.
文摘In 2022,gastric cancer(GC)ranked as the fifth most common cancer and the third leading cause of cancer death in China,with 358,672 new cases and 260,372 deaths,accounting for 37.0%and 39.4%of global cases,respectively[1].Previous studies have shown that 25.9%and 36.5%of GC patients in China were diagnosed at stages III and IV,respectively,with 5-year overall survival(OS)rates of 33.0%for stage III and 5.5%for stage IV[2,3].
文摘Large granular lymphocytic leukemia(LGLL)is a relatively uncommon malignancy of the blood system,marked by the clonal expansion of cytotoxic lymphocytes,particularly CD8+T cells(T-LGLL),and in some cases,natural killer(NK)cells(NK-LGLL).1 Though rare,LGLL is clinically significant,representing approximately 2%to 6%of all chronic lymphopro-liferative diseases,with a somewhat higher incidence in Asian populations.
文摘Objective： The mitomycin C and cisplatin combination was investigated in patients with advanced breast cancer who had been exposed to anthracyclines, vinorelbine and taxanes. Methods： Three-weekly regimen consisted of mitomycin, 6 mg/m^2 administered intravenously on day 1, and cisplatin, 25 mg/m^2 intravenously on day 1-3. Results： Thirty-eight patients aged 25-75 years （median, 46 years） were treated with an overall response rate of 31.6%. The median time to progression （TTP） was 4.0 months. Median TTP for 12 patients with a complete or partial response was 9.0 months, while stable disease and progression of disease 4.0 months, P=0.002. Grade 3/4 side effects of neutropenia, thrombocytopenia and nausea/vomiting were documented in 4 （10.5%）, 4 （10.5%） and 3 （7.9%） patients, respectively. The median overall survival was 13＊ months. Conclusion： Mitomydn C/cisplatin doublet showed antitumor activity for anthracydine-, vinorelbine- and taxane-resistant breast cancer comparable to other regimens. This well-tolerated regimen provides an affordable option for patients in China.
